U.S. Pauses Distribution Of Monoclonal Antibody Treatments That Proved Ineffective Against Omicron

Share

Forbes Breaking News

The U.S. government has paused distribution of COVID-19 monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly, saying those treatments are probably ineffective against the omicron variant, while some hospitals struggle with limited supply of GlaxoSmithKline and Vir Biotechnology’s more effective treatment.

Dec 23, 2021